MX2015000804A - Treating ewing's sarcoma and ews-fli1 related disorders. - Google Patents
Treating ewing's sarcoma and ews-fli1 related disorders.Info
- Publication number
- MX2015000804A MX2015000804A MX2015000804A MX2015000804A MX2015000804A MX 2015000804 A MX2015000804 A MX 2015000804A MX 2015000804 A MX2015000804 A MX 2015000804A MX 2015000804 A MX2015000804 A MX 2015000804A MX 2015000804 A MX2015000804 A MX 2015000804A
- Authority
- MX
- Mexico
- Prior art keywords
- fli1
- ews
- sarcoma
- related disorders
- treating ewing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The field relates to compositions and methods for treating Ewing's Sarcoma and other disorders related to EWS-FLI1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261674047P | 2012-07-20 | 2012-07-20 | |
| PCT/US2013/051105 WO2014015153A2 (en) | 2012-07-20 | 2013-07-18 | Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015000804A true MX2015000804A (en) | 2016-03-11 |
Family
ID=49949378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000804A MX2015000804A (en) | 2012-07-20 | 2013-07-18 | Treating ewing's sarcoma and ews-fli1 related disorders. |
Country Status (2)
| Country | Link |
|---|---|
| MX (1) | MX2015000804A (en) |
| WO (1) | WO2014015153A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204376B1 (en) * | 2014-10-09 | 2023-04-19 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
| EP3436434B1 (en) | 2016-03-31 | 2020-07-08 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| US10159660B2 (en) | 2016-07-29 | 2018-12-25 | Oncternal Therapeutics, Inc. | Uses of indolinone compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
| KR101379364B1 (en) * | 2005-02-08 | 2014-03-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Compositions involving MDA-7 for the treatment of cancer |
| US8232310B2 (en) * | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| PL2299984T3 (en) * | 2008-05-15 | 2019-07-31 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| CA2712747A1 (en) * | 2010-08-11 | 2012-02-11 | Universite De Montreal | Combinatory cancer treatment |
-
2013
- 2013-07-18 WO PCT/US2013/051105 patent/WO2014015153A2/en active Application Filing
- 2013-07-18 MX MX2015000804A patent/MX2015000804A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014015153A2 (en) | 2014-01-23 |
| WO2014015153A3 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX365614B (en) | Compositions useful for treating disorders related to kit. | |
| JO3343B1 (en) | Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use | |
| PH12016500953A1 (en) | Tricyclic compounds as anticancer agents | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| MX2019008122A (en) | Heterocycle amines and uses thereof. | |
| WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
| MX2015012502A (en) | Dna-pk inhibitors. | |
| IN2015DN00438A (en) | ||
| MY189912A (en) | Substituted xanthines and methods of use thereof | |
| RS53893B1 (en) | Use of biotin for the treatment of multiple sclerosis | |
| IN2014DN09228A (en) | ||
| MX2016005760A (en) | Gsk-3 inhibitors. | |
| MX2016003823A (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma. | |
| IN2014DN06104A (en) | ||
| PH12015502665A1 (en) | Improvements in or relating to organic compounds | |
| WO2012027482A3 (en) | Compounds, compositions and methods related to ppar antagonists | |
| IN2014DN11078A (en) | ||
| IN2014DN08412A (en) | ||
| MY191337A (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| MX2015009277A (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine. | |
| MX2015000804A (en) | Treating ewing's sarcoma and ews-fli1 related disorders. | |
| NZ717192A (en) | Anti-inflammatory tripeptides | |
| UA117567C2 (en) | Galactagogue compositions based on phosphatidylserine | |
| PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
| EA201491522A1 (en) | METHODS OF TREATING DISORDERS OF GAIT AND / OR BALANCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AMINOPYRIDINE |